Por Renan Filho · 2026-10-12**Lead** A Biden-appointed federal judge presiding over a high-stakes antitrust case erupted at Department of Justice lawyers during a hearing on Tuesday, accusing them of relying on discredited economic models and declaring, “You’ve lost all credibility!” The outburst sent shockwaves through the courtroom as the judge questioned the government’s entire approach to challenging a proposed mega-merger in the pharmaceutical industry.
**Context** The judge, who was elevated to the bench by President Biden in 2022 and has a well-documented history of sharp exchanges with attorneys from both the Trump and Biden administrations, is overseeing a lawsuit that seeks to block a $30 billion acquisition of a drug manufacturer by a larger competitor. The DOJ’s Antitrust Division argues that the merger would allow the combined entity to control more than 60% of the market for a critical class of cardiovascular medications, leading to higher prices for patients and insurers.
During the hearing, the judge grew visibly frustrated as DOJ attorneys presented a series of economic simulations meant to predict post-merger price increases. “I’ve read your expert reports, and I’ve read the defendants’ rebuttals,” the judge told the government’s lead counsel. “The assumptions you are making are not just speculative – they are contradicted by your own internal data. At this point, I have to say, you’ve lost all credibility with this court.” Defense attorneys, representing the merging companies, did not immediately react but later cited the judge’s remarks in a motion to dismiss the case.
The clash is the latest in a series of contentious moments involving this judge, who previously sparred with Trump-era officials over immigration policy and executive privilege. In one notable 2023 ruling, the judge sharply criticized the DOJ’s handling of evidence in a separate antitrust case, calling the agency’s arguments “unpersuasive and, at times, disingenuous.” Legal experts say such outspokenness from the bench is unusual, especially in economic cases where judges typically defer to the government’s expert opinions.
**Analise** The judge’s eruption carries significant implications for federal antitrust enforcement. If the court ultimately rules against the DOJ – or forces the government to overhaul its economic analysis – it could set a precedent that makes it harder for regulators to block mergers based on predictive market models. “This is not just a single judge losing patience,” said a former DOJ antitrust attorney who spoke on condition of anonymity. “It reflects a growing skepticism in the judiciary about the rigor of the government’s economic evidence. If judges start demanding ironclad data before accepting merger challenges, the entire enforcement landscape changes.”
The pharmaceutical merger at the center of the case is seen as a bellwether for the Biden administration’s aggressive antitrust stance under Assistant Attorney General Jonathan Kanter. The DOJ has vowed to rein in consolidation in industries ranging from healthcare to technology, but the judge’s rebuke suggests that some courts are pushing back against what they perceive as overreach. Market analysts have noted that the uncertainty surrounding the case has already depressed merger activity in the sector, with deal values falling 12% year-over-year as companies wait to see how the judge rules.
Moreover, the judge’s public questioning of the DOJ’s credibility may embolden defendants in other antitrust cases to more aggressively challenge the government’s economic evidence. “The judiciary is sending a message that expert testimony must be grounded in real-world data, not just theoretical models,” said a professor of antitrust law at Georgetown University. “This could lead to more rigorous discovery and cross-examination of DOJ experts, which in turn could slow down enforcement actions.”
**Fontes** - Court transcripts from the hearing (filed in the U.S. District Court for the relevant district, case number not disclosed pending final ruling). - Statements from the DOJ Antitrust Division, public filings dated October 2026. - Legal analysis and commentary from antitrust experts cited in Bloomberg Law and The Wall Street Journal. - Previous rulings by the same judge, available on PACER and referenced in legal databases.